retatrutide fda approval status november 2025 Commercial Availability Timeline: Key Milestones and Costs Retatrutide, an experimental weight-loss drug,

The James Ross Basin (northeastern Antarctic Peninsula) preserves marine-to-terrestrial deposits spanning the Aptian to Oligocene and offers an opportunity to expand southern high-latitude diatom biostratigraphy and to document paleoenvironmental changes

In this context, walkability plays a critical role in the design of livable cities

It contains semaglutide, the same active ingredient as Ozempic, made by Novo Nordisk, but at higher doses and licensed specifically for weight loss rather than type 2 diabetes

doi: 10.1016/j.physbeh.2004.02.012 121 SmithGP

In the Phase 3 TRIUMPH-4 trial, participants on the highest dose (12 mg) lost an average of 28.7% of their body weight over 68 weeks